Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Deferred Taxes (2020 - 2024)

Revolution Medicines' quarterly Deferred Taxes came in at $762000.0 in Q4 2024, up 1672.09% year-on-year from $43000.0 in Q1 2024, and up 1672.09% quarter-over-quarter from $43000.0 in Q4 2023.

Revolution Medicines has reported Deferred Taxes for 4 years, with the latest figure at $762000.0 in Q4 2024.

  • For the quarter ending Q4 2024, Deferred Taxes rose 1672.09% year-over-year to $762000.0; the trailing twelve-month figure through Dec 2024 stood at $928000.0 (up 580.83% YoY), and the FY2024 full-year result was $762000.0, down 80.51% from the prior year.
  • Deferred Taxes for Q4 2024 stood at $762000.0, up from $43000.0 in the prior quarter.
  • The five-year high for Deferred Taxes was $762000.0 in Q4 2024, with the low at -$359000.0 in Q4 2020.
  • Average Deferred Taxes over 4 years is $217166.7, with a median of $83000.0 recorded in 2022.
  • Year-over-year, Deferred Taxes tumbled 65.04% in 2023 and jumped 1672.09% in 2024.
  • Tracing RVMD's Deferred Taxes over 4 years: stood at -$359000.0 in 2020, then soared by 134.26% to $123000.0 in 2022, then plunged by 65.04% to $43000.0 in 2023, then jumped by 1672.09% to $762000.0 in 2024.
  • The last three Deferred Taxes figures came in at $762000.0 (Q4 2024), $43000.0 (Q4 2023), and $123000.0 (Q4 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Deferred Taxes (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -859,000.00
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -65.30 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 96.00 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 9.31 Mn
10 Revolution Medicines 31.20 Bn 31.20 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 762,000.00
Dec 31, 2023 43,000.00
Dec 31, 2022 123,000.00
Dec 31, 2020 -359,000.00
Jun 30, 2020 18,000.00
Mar 31, 2020 716,000.00